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ORIGINAL ARTICLE
The drebrin/EB3 pathway drives invasive activity in
prostate cancer
AE Dart1, DC Worth1, G Muir2, A Chandra3, JD Morris4, C McKee5, C Verrill6, RJ Bryant6 and PR Gordon-Weeks1
Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the
drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin ﬁlament interactions underlying cell shape changes in
response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in
benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in
human prostate cancer cell lines and co-localizes with actin ﬁlaments and dynamic microtubules in ﬁlopodia of pseudopods of
invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small
molecule inhibitor of drebrin binding to actin ﬁlaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays.
Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases
invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that
competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our ﬁndings show
that co-ordination of dynamic microtubules and actin ﬁlaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and
is therefore implicated in disease progression.
Oncogene advance online publication, 20 March 2017; doi:10.1038/onc.2017.45
INTRODUCTION
Drebrin is a ﬁlamentous actin (F-actin)-binding protein with roles
in neuronal development and synaptic plasticity.1 Drebrin couples
dynamic microtubules to F-actin in ﬁlopodia during neuritogen-
esis and in dendritic spines by binding to the microtubule-binding
+TIP protein EB3.2,3 There are two domains in the N-terminal half
of drebrin, which independently bind to F-actin.4 These two
domains act co-operatively to bundle F-actin but this activity is
repressed by an intramolecular interaction that is relieved by Cdk5
phosphorylation of S142.4 Drebrin has a role in oculomotor
neuron migration,5 and phospho-mimetic and phospho-dead
mutants of S142 enhance and inhibit neuritogenesis, respectively.4
Furthermore, either mutant inhibits cerebral cortical neuronal
migration6 and migration of olfactory bulb precursor neurons,7
implying that regulation of this phosphorylation is crucial to
neuronal migration. Cell migration is important for cancer
progression and the demonstrated role for drebrin in neuronal
migration therefore prompted us to investigate a possible role for
the drebrin/EB3 pathway in cancer cell invasion.
Prostate cancer is the most common malignancy diagnosed in
men in the Western world and the second leading cause of male
cancer-related death.8 Malignant cells most likely arise from either
a failure of the appropriate differentiation of basal epithelial cells
that normally give rise to both basal and luminal epithelial cells, or
from a failure of luminal cell differentiation,9–11 and processes
such as epithelial-to-mesenchymal transition result in the acquisi-
tion of an invasive cancer cell phenotype.12 Prostate cancer cells
commonly metastasise to bone and there is evidence that the
chemokine CXCL12, acting through its cognate receptor CXCR4,
plays a role in bone metastasis.13–16 Here we show that drebrin, an
actin ﬁlament-binding protein that also binds to the CXCR4
receptor,17 and EB3 a microtubule +TIP protein in the drebrin/EB3
pathway, contribute to prostate cancer cell invasion.
RESULTS
Drebrin and pS142-drebrin are upregulated in malignant prostate
In sections of benign human prostate, drebrin co-localizes with
F-actin in a population of epithelial cells (Figure 1a). These cells
express the basal cell marker p63, and are therefore likely to be
basal prostate epithelial cells (Figure 1b).11,18 Consistent with this
identity, drebrin-expressing cells contact the basal lamina that
surrounds the glands, as revealed by labelling with laminin
antibodies (Figure 1c). Luminal cells in the glands do not express
drebrin but, unlike the basal cells, contain bundles of vimentin
intermediate ﬁlaments and cytokeratin 8 (not shown).
In sections of human prostate cancer tissue, in addition to
drebrin-positive basal epithelial cells in areas with benign glands,
we found glands in which luminal epithelial cells also expressed
drebrin (Figure 1d). Luminal epithelial cells expressing drebrin also
expressed the luminal cell markers cytokeratin 8 (Figure 1e) and
vimentin (not shown), thereby conﬁrming their identity.11 We
conﬁrmed the presence of drebrin in malignant and benign
prostate by immunoblotting and found that the levels of drebrin
were signiﬁcantly greater in malignant tissue (Figures 1f and g).
We also detected pS142-drebrin in malignant samples, although,
despite correspondingly increased levels of p35 and Cdk5 in
malignant tissue, these were not always higher than in benign
prostate (Figures 1f and g).
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To investigate the expression of drebrin and pS142-drebrin in a
larger cohort of benign and malignant prostate tissue samples we
analysed a tissue microarray of human prostate sections from
patients who had undergone radical prostatectomy as primary
treatment for prostate cancer. We immunolabelled the tissue
microarray with either drebrin or pS142-drebrin antibodies and
observed that drebrin and pS142-drebrin localized to the
cytoplasm and plasma membrane of both benign and malignant
prostate epithelial cells (Supplementary Figure S1A–D). Cytoplasmic
drebrin expression and membranous pS142-drebrin expression
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were signiﬁcantly higher in prostate cancer samples compared
with benign samples (Supplementary Figure S1E and F). To
uncover potential associations between altered drebrin expression
and clinical outcome in prostate cancer we interrogated data
(mRNA expression changes and copy number variations) from the
publically available MSKCC Prostate Cancer Genomics Data Portal
data set.19 We found that both increased mRNA expression and
copy number gain of drebrin, Cdk5 and Cdk5R1 (p35, the
regulatory subunit of Cdk5), occur signiﬁcantly more frequently
in prostate cancer metastasis samples (n= 37) than in primary
(that is, organ-conﬁned, n= 179) prostate cancer samples
(Supplementary Figure S2). In addition, patients in this cohort
with prostate cancer containing a genetic alteration in Cdk5R1
(p35) had a signiﬁcantly reduced disease-free survival following
treatment (Supplementary Figure S3), and a similar trend was
observed for drebrin and Cdk5 although these latter two proteins
did not reach statistical signiﬁcance. Signiﬁcant positive correla-
tions were observed between mRNA expression levels of drebrin,
Cdk5 and Cdk5R1 (Supplementary Figure S3). Taken together
these results suggest that prostate cancer metastases more
frequently harbour genetic changes associated with over-
expression of drebrin, and proteins regulating drebrin’s actin
bundling activity, as compared with primary prostate cancer
samples, raising the possibility that these events might promote
(or at least be associated with) prostate cancer progression to a
metastatic phenotype.
Drebrin and pS142-drebrin are upregulated in prostate cancer cell
lines and co-localize with dynamic microtubules and F-actin in
ﬁlopodia
We screened a panel of human prostate cancer cell lines (LNCaP,
DU-145, PC-3) and a non-malignant human prostate epithelial cell
line (PNT2-C2) for drebrin expression (Figure 2a). We detected
moderate levels of drebrin in PNT2-C2 cells and higher levels in
DU-145 cells and LNCaP cells. PC-3 cells had the highest levels of
drebrin compared to PNT2-C2 cells (Figures 2a and b). To
investigate the levels of Cdk5-phosphorylated drebrin we used
pS142-drebrin antibodies.4 This showed that pS142-drebrin is
present in all prostate cancer cell lines examined and that the
levels are proportional to the levels of drebrin (Figures 2a and b).
The levels of pS142-drebrin do not correlate with Cdk5R1 (p35),
the regulatory subunit of Cdk5 or with Cdk5 (Figure 2b).
We cultured PC-3 cells in 3D Matrigel in a gradient of CXCL12,
since they express CXCR4, the cognate receptor for this
chemokine.14 PC-3 cells were initially rounded and extended
ﬁlopodia in all directions (Figure 2c). In these cells, drebrin was
distributed around the cell cortex co-localizing with F-actin
(Figure 2c). Subsequently, ﬁlopodia on the side of the cell facing
the gradient became noticeably longer than those on the
opposite side (Figure 2d). Drebrin and dynamic microtubules,
identiﬁed by immunolabelling with an antibody to dynamic
microtubules,20 became localized to these longer ﬁlopodia
(Figure 2d). Eventually, most cells became elongated and
polarized, with large, ﬁlopodia-covered pseudopods containing
drebrin and dynamic microtubules (Figure 2e).
To explore whether the CXCL12/CXCR4 axis signals directly to
the drebrin/EB3 pathway we looked for an effect of CXCL12 on
drebrin phosphorylation at S142. We treated PC-3 cells in culture
with CXCL12 and conﬁrmed previous reports21 that CXCL12
induces extracellular signal-regulated kinase (ERK) phosphoryla-
tion (Supplementary Figure S4). In addition, we found a slight,
time-dependent decline in pS142-drebrin levels, although this did
not reach statistical signiﬁcance (Supplementary Figure S4).
BTP2, an inhibitor of drebrin binding to F-actin, reduces PC-3 cell
invasion
To assess whether drebrin has a role in PC-3 cell invasion we
tested the effect of BTP2, a small molecule inhibitor of drebrin
binding to F-actin,22 in a 3D Matrigel Transwell invasion assay
using CXCL12 as a chemoattractant. BTP2 produced a dose-
dependent reduction in the number of PC-3 cells that passed
through the insert ﬁlter compared to vehicle-treated cells
(Figures 3a–c). The lowest concentration of BTP2 used (0.5 μM)
produced inhibition and maximal inhibition of 63% occurred with
10 μM BTP2 (Figure 3c). We checked whether changes in cell
viability or adhesion to Matrigel might contribute to inhibition of
invasion produced by BTP2 (Supplementary Figure S5A and B).
This showed that BTP2 reduces cell viability and cell adhesion only
at 10 μM and therefore could not account for the inhibition of PC-3
cell invasion.
Figure 1. Drebrin is expressed in basal epithelial cells in non-malignant human prostate and upregulated in luminal epithelial cells in human
prostate cancer tissue. (a) Drebrin is expressed by a population of cells in the glandular epithelium of benign human prostate hyperplasia,
where it co-localizes with F-actin. Immunoﬂuorescence images of human prostate tissue labelled with an antibody to drebrin and phalloidin
to label F-actin. Drebrin in basal cells co-localizes with F-actin (arrows). Luminal cells (arrowheads) do not contain drebrin and therefore
drebrin is not associated with the F-actin in the terminal junctional web of luminal cells (curved arrow). (b) Drebrin-expressing epithelial cells
also express the transcription factor protein p63, a basal cell marker, in their nucleus. Immunoﬂuorescence images of human non-malignant
prostate tissue labelled with antibodies to drebrin and p63 and with phalloidin to label F-actin. Drebrin (arrows) is expressed in cells that also
express nuclear p63 (asterisks) and co-localizes with F-actin (arrows). Drebrin is not associated with the F-actin in the terminal junctional web
of luminal cells (curved arrows). (c) Drebrin is expressed by cells that contact the basal lamina in the glandular epithelium of non-malignant
human prostate. Immunoﬂuorescence images of human prostate tissue labelled with antibodies to drebrin and to laminin to label the basal
lamina, and with phalloidin to label F-actin. Drebrin is present in basal cells (arrows) that contact the basal lamina (arrowheads) and
co-localizes with F-actin. Luminal epithelial cells do not express drebrin (asterisks). (d) Drebrin is upregulated in luminal epithelial cells in the
glands of malignant human prostate tissue. Immunoﬂuorescence images of malignant human prostate tissue labelled with antibodies to
drebrin and laminin, to label the basal lamina and phalloidin to label F-actin. In luminal epithelial cells drebrin is particularly localized to baso-
lateral bundles of F-actin (arrows). The glands have a disorganized architecture and there are no F-actin terminal webs visible. Notably the
basal lamina appears to be deﬁcient as indicated (curved arrows). (e) Luminal epithelial cells upregulating drebrin express cytokeratin 8,
conﬁrming their luminal phenotype. Immunoﬂuorescence images of malignant human prostate tissue labelled with antibodies to drebrin and
cytokeratin 8, and with phalloidin to label F-actin. Drebrin is expressed in cells throughout the acinus including luminal cells that also express
cytokeratin 8, a marker for luminal cells (arrows). Drebrin in these cells co-localizes with F-actin. The acinus is the same one shown in d (white
box area) but from an adjacent section. (f) Immunoblot of three individual cases of benign human prostate hyperplasia (B1–B3) and three
individual cases of human prostate cancer (M1–M3) probed with antibodies to drebrin, pS142-drebrin, Cdk5, p35 and GAPDH, as a loading
control. Drebrin is expressed in benign prostate tissue and upregulated in malignant prostate tissue. Despite upregulation of Cdk5 and p35 in
malignant prostate, pS142-drebrin is variably expressed in malignant prostate. The lower band of the pS142-drebrin blot is a breakdown
product of drebrin. (g) Quantiﬁcation of relative drebrin and pS142-drebrin protein levels normalized to GAPDH and drebrin, respectively,
from immunoblots of benign (B1–B3) and malignant (M1–M3) prostate tissue. Error bars are mean± s.e.m. from three replicate samples.
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Binding of BTP2 to drebrin requires two adjacent lysines: K270
and K271 in human drebrin.22 Mutation of these lysines to
methionine abrogates BTP2 binding but does not affect drebrin
binding to F-actin.22 We used the K270M, K271M drebrin mutant
to directly test the role of drebrin in the inhibition of invasion
produced by BTP2. We transfected PC-3 cells with wild-type
Figure 2. Drebrin and pS142-drebrin are upregulated in human prostate cancer cell lines. (a) Immunoblots of human prostate epithelial cell
lines probed with antibodies against drebrin, pS142-drebrin, Cdk5, p35 and, as a loading control, GAPDH. Drebrin is expressed at moderate
levels in the normal human prostate epithelial cell line PNT2-C2 and the human prostate cancer cell line DU-145, and at higher levels in the
human prostate cancer cell lines LNCaP and PC-3. There is a tight correlation between the levels of drebrin and pS142-drebrin. p35 is highly
upregulated in prostate cancer cell lines compared to PNT2-C2 cells. (b) Quantiﬁcation of relative protein levels from immunoblots of PNT2-C2,
LNCaP, DU-145 and PC-3 cell lysates probed with antibodies against drebrin, pS142-drebrin, Cdk5 and p35. Error bars are mean± s.e.m. from at
least three independent experiments. Signiﬁcant differences: *Po0.05; **Po0.01. (c–e) Immunoﬂuorescence images of PC-3 cells in 3D
Matrigel in a CXCL12 gradient in chemotaxis chambers. The source of CXCL12 is to the left. Cells were labelled with antibodies against drebrin
and tyrosinated α-tubulin (tyr-tubulin), to identify dynamic microtubules, and with phalloidin, to label F-actin. (c) An unpolarized, rounded cell
with F-actin containing ﬁlopodia extended in all directions (arrowheads). Drebrin is distributed in the cell cortex co-localizing with F-actin.
(d) A polarized cell before pseudopod production. The longest ﬁlopodia are extended on the side of the cell facing the CXCL12 gradient
(arrowheads). Dynamic microtubules (tyr-tubulin) have entered the ﬁlopodia facing the gradient and drebrin has re-located to their base.
(e) A polarized cell with several pseudopods (asterisks) covered in ﬁlopodia (arrowheads). Drebrin strongly co-localizes with F-actin,
particularly at the base of ﬁlopodia (arrowheads). Large bundles of dynamic microtubules (tyr-tubulin) enter pseudopods and single or small
bundles of microtubules enter some ﬁlopodia (curved arrow).
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drebrin-green ﬂuorescent protein (GFP), K270M, K271M drebrin-
GFP or GFP and compared the effects of BTP2 treatment on
invasion of these cells in the 3D invasion assay. Immunoblotting
showed similar levels of expression with the three constructs
(Figure 3d). The K270M, K271M drebrin-GFP construct rescued the
BTP2 inhibitory effect on PC-3 cell invasion in 3D assays
(Figure 3e), showing that the action of BTP2 on PC-3 invasion is
mediated by binding to drebrin. Expression of the K270M, K271M
drebrin-GFP construct produced the same relative proportion of
invaded cells as expression of drebrin-GFP and both constructs
became phosphorylated on S142 (Supplementary Figure S6A and
B) suggesting that K270M, K271M drebrin-GFP behaves like wild-
type drebrin.
Drebrin knockdown or over-expression inhibits or enhances
prostate cancer cell invasion respectively
Transfection of PC-3 or LNCaP C4-2B cells with either of two,
independent, drebrin-speciﬁc siRNAs reduced drebrin levels in
PC-3 cells by 485%, as demonstrated by quantitative immuno-
blotting (Figures 3f and g; Supplementary Figure S7A and B).
Drebrin knockdown inhibited PC-3 and LNCaP C4-2B cell invasion
in 3D assays to a similar extent as that seen with BTP2 (Figure 3h;
Supplementary Figure S7C). Cell viability assays showed that
the effect of drebrin-speciﬁc siRNA is not due to cell death
(Supplementary Figure S7C). Conversely, expression of drebrin-YFP
in PC-3 cells increased cell invasion in 3D assays compared to
expression of YFP alone (Figure 3i). These ﬁndings independently
conﬁrm a role for drebrin in PC-3 cell invasion.
BTP2 treatment or drebrin knockdown inhibits PC-3 cell invasion
by attenuating polarization and the chemotactic response to a
CXCL12 gradient
We used phase contrast microscopy to image PC-3 cells in
chemotaxis chambers with CXCL12 gradients (Figure 4). After 48 h
in the chemotactic gradient we found examples of cells migrating
in the direction of the CXCL12 gradient while leaving behind a
degradation trail in the Matrigel that was visible in phase contrast
(Figure 4a, white arrowheads).23 In the absence of a CXCL12
gradient the orientation of degradation trails of untreated PC-3
cells or cells transfected with control siRNA showed a slight
preference in one direction but the conﬁdence limits were large
and unreliable (Figures 4b and c). In the presence of a CXCL12
gradient, degradation trails of vehicle-treated PC-3 cells or cells
transfected with control siRNA were preferentially oriented toward
the gradient (Figures 4b and c) whereas the degradation trails of
PC-3 cells treated with BTP2 or transfected with drebrin siRNA
showed no preferred orientation (Figures 4b and c).
To investigate whether drebrin affects polarization of PC-3 cells
in 3D in the presence of CXCL12 gradients we compared the
length of ﬁlopodia on the gradient-facing side of rounded cells,
before they had produced pseudopods, with the length of
ﬁlopodia on the opposite side (Figure 4d). After 24 h in the
chemotactic gradient, PC-3 cells transfected with control siRNA
had longer ﬁlopodia on the gradient-facing side of the cell than on
the opposite side (Figure 4d). In contrast, PC-3 cells transfected
with drebrin siRNA, showed no difference in ﬁlopodia length
between the two sides of the cell (Figure 4d). This ﬁnding suggests
that drebrin contributes to ﬁlopodia polarization during the early
stages of cell polarization. Consistent with this idea, drebrin
becomes localized particularly to the longer ﬁlopodia on the side
of the cell facing the CXCL12 gradient (Figure 2d) and these
ﬁlopodia are more commonly penetrated by dynamic micro-
tubules (Figures 2d and 4e).
Together these ﬁndings suggest that drebrin plays a role in the
chemotactic response to CXCL12. To determine whether drebrin
also plays a role in prostate cancer cell motility, PC-3 cells were
plated into 6-well dishes coated with ﬁbronectin and imaged by
phase contrast microscopy in the presence of DMSO (vehicle
control) or different concentrations of BTP2 to inhibit drebrin
binding to F-actin. Cell motility was measured from 100 images
captured every 10 min. This showed that BTP2 maximally reduces
PC-3 cell motility by about 50% (Supplementary Figure S8),
implying that drebrin also contributes to cell motility.
EB3M, a dominant-negative construct of the drebrin/EB3 pathway,
inhibits PC-3 cell invasion
Drebrin binds to the microtubule +TIP protein EB3, but not to the
closely related family member EB1, and this interaction couples
dynamic microtubules to F-actin.2,4,24,25 The drebrin-binding site is
in the mid-region of EB3 and a construct encoding this region
(EB3M) acts as a dominant-negative.2 The relative levels of EB1
and EB3 vary between prostate cancer cell lines (Figure 5a). Lower
levels of EB3 than EB1 were found in PNT2-C2 and PC-3 cells, but
higher levels of EB3 than EB1 were observed in LNCaP and DU-145
cells (Figure 5a). We tested the effects of cyan ﬂuorescent protein
(CFP), CFP-EB1, CFP-EB1M (encoding the homologous mid-region
of EB1), CFP-EB3 and CFP-EB3M on PC-3 cell invasion through
Matrigel (Figures 5b and c). We obtained similar levels of protein
expression of related constructs (Figure 5b). Expression of CFP-EB1
or CFP-EB3 increased PC-3 cell invasion through Matrigel in 3D
assays by 39 and 80%, respectively, compared to CFP alone. In
contrast, CFP-EB3M reduced PC-3 cell invasion by 51%, whereas
CFP-EB1M reduced PC-3 cell invasion by only 17%, which was not
signiﬁcant (Figure 5c). Transfection of PC-3 cells with CFP-EB3M,
but not with CFP-EB1M, dramatically altered their morphology
(Figure 5d). CFP-EB3M-expressing cells were distinctly rounded
with no pseudopods, which might contribute to their invasion
defect (Figure 5d). These results suggest that an interaction
between drebrin and EB3 is important for PC-3 cell invasion of
Matrigel in CXCL12 gradients.
EB1 and EB3 contribute to prostate cancer cell invasion in
response to a CXCL12 gradient
The +TIP proteins EB1 and EB3 have distinct distributions at the
plus-end of dynamic microtubules in PC-3 (Figure 6a) and LNCaP
C4-2B cells (not shown). EB1 is located closer to the microtubule
plus-end than EB3 and occupies a shorter length of the
microtubule (Figures 6a and b). Fluorescence intensity line plots
showed that the average length of EB1 and EB3 distribution
along the microtubule lattice was 1.05 ± 0.03 μm (mean± s.e.m.,
n= 100) and 2.655 ± 0.05 μm (mean± s.e.m., n= 100), respectively
(Figures 6b and c). Transfection of PC-3 or LNCaP C4-2B cells with
either of two, independent, EB1- or EB3-speciﬁc siRNAs reduced
EB1 and EB3 protein levels by greater than 85 and 70%
respectively, as shown by quantitative immunoblotting (Figure 6d,
Supplementary Figure S9A–F). EB1 knockdown did not change
the length distribution of EB3 at the microtubule plus-end
(Figures 6c and e). EB3 knockdown, however, increased the length
of EB1 distribution along the microtubule to an average of
2.71± 0.04 μm (mean± s.e.m., n=100; Figures 6c and e). EB1 or
EB3 knockdown in PC-3 or LNCaP C4-2B cells reduced invasion of
Matrigel in CXCL12 gradients, with EB3 knockdown having the
greater effect (Figure 6f and Supplementary Figure S9G and H). Cell
viability assays showed that the effect of EB-speciﬁc siRNA is not
due to cell death (Supplementary Figure S5C). The effect of EB3
knockdown on prostate cancer cell invasion of Matrigel is consistent
with the involvement of the drebrin/EB3 pathway in this process.
It has been reported that knockdown of EB1 produced no
change in microtubule dynamics in undifferentiated myoblasts
(C2C12 cells)26 or CHO-K127 cells but shortened microtubules in
Sertoli cells.28 EB3 knockdown produced curly microtubules in
C2C12 cells26 but had no effect on dynamic microtubules
in CHO-K1 cells.27 To test whether EB1 or EB3 knockdown affects
microtubule dynamics in prostate cancer cell lines we assessed the
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morphology and distribution of dynamic microtubules in cells
lacking EB1 or EB3 by labelling with an antibody against dynamic
microtubules. This showed that neither EB1 nor EB3 knockdown
affected the morphology of dynamic microtubules or prevented
microtubules from extending to the cell periphery (Supplementary
Figure S10) implying that the effects of EB3 knockdown on
Drebrin/EB3 and prostate cancer invasion
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prostate cancer cell invasion are primarily due to loss of EB3 from
microtubules and not secondarily due to changes in microtubule
dynamics.
DISCUSSION
We show here that drebrin is expressed in basal, but not luminal,
epithelial cells in normal human prostate glands and is
upregulated in luminal epithelial cells in malignant glands. An
upregulation of drebrin in malignant tissue was conﬁrmed by
quantitative immunoblotting. We also found high expression of
drebrin in PC-3 and LNCaP C4-2B cells, which are human prostate
cancer cell lines isolated from metastatic tissue, further supporting
the idea that drebrin expression might be dysregulated in prostate
cancer and contribute to metastatic activity. Drebrin is dysregu-
lated in several cancers.29–33 Genomic analysis implicates drebrin
copy number gain in 11% of prostate cancer cases.19 Our
observation that drebrin mRNA upregulation and copy number
gain occurs signiﬁcantly more frequently in prostate cancer
metastasis samples than in material from primary prostate cancers
raises the possibility that an increase in drebrin expression could
promote prostate cancer progression, though it is also possible
that these genetic events may be a consequence of metastasis
formation, perhaps reﬂecting changes in the tumour microenvir-
onment. p35 and Cdk5 are also upregulated in prostate cancer
and prostate cancer cell lines and Cdk5 activity has previously
been shown to contribute to prostate cancer cell motility.34 These
ﬁndings suggest, therefore, that the drebrin/EB3 pathway as a
whole is dysregulated in prostate cancer.
We found evidence that the drebrin/EB3 pathway is important
in prostate cancer cell invasion and the chemotactic response to
the chemokine CXCL12. BTP2, an inhibitor of drebrin F-actin-
binding, and drebrin and EB3 knockdown impaired prostate
cancer cell invasion whereas drebrin and EB3 over-expression
enhanced it. Drebrin binds to CXCR4 and recruits CXCR4 to the
immunological synapse.17 CXCL12 signalling can promote pros-
tate cancer cell invasion through an extracellular matrix, and trans-
migration across bone marrow endothelial cell monolayers.13
Furthermore, blockade of CXCR4 prevents metastasis in prostate
metastatic in vivo models.15 In line with our work and other
studies of prostate cancer, the CXCL12/CXCR4 pathway has also
been shown to increase the chemotactic and invasive behaviour
of breast cancer cells and silencing CXCR4 prevents breast cancer
metastatic spread in experimental mouse models.35–38 Our
experiments, however, do not answer the question of whether
drebrin facilitates prostate cancer cell invasion through its role in
CXCL12/CXCR4 signalling, or by coupling F-actin to dynamic
microtubules, or by both mechanisms. There is evidence that
CXCL12/CXCR4 signalling associated with lipid rafts is important in
driving prostate cancer cell metastasis in bone39 but there is no
evidence that drebrin associates with lipid rafts.40 Co-ordination of
the microtubule and F-actin cytoskeletons mediated by the
drebrin/EB3 pathway occurs in ﬁlopodia leading to their stabiliza-
tion in response to extrinsic cues.3 There is mounting evidence
that ﬁlopodia are important in the polarization and guided
movement of cancer cells in 3D and in cancer metastasis and
invasion,41 an idea supported by the ﬁndings reported here.
An unexpected ﬁnding was that EB1 and EB3 occupy different
regions along the microtubule lattice; EB1 has a shorter and more
distal location while EB3 occupies a longer stretch of the microtubule
lattice and is more proximal. EB1 recognizes GTP-bound tubulin in
the GTP-cap region at the plus-end of microtubules.42 The more
proximal binding of EB3 is consistent with EB3 recognizing GDP-
bound tubulin. The differential localization of these two +TIP
proteins on the same microtubule has implications for the
consequences of drebrin binding to EB3. Because EB1 is more
distally located on the microtubule lattice than EB3, the growth of a
microtubule cross-linked through the drebrin/EB3 pathway to actin
ﬁlaments at the base of a ﬁlopodium would probably not be
impeded. As the microtubule extends into the ﬁlopodium, iterative
proximo-distal addition of drebrin/EB3-mediated cross-links would
produce a zippering-up effect of the microtubule to F-actin in the
ﬁlopodium. Consistent with this, the dynamic behaviour of drebrin,
in which drebrin extends proximo-distally into the ﬁlopodium,
predicted by a zippering-up effect, has been observed.2
MATERIALS AND METHODS
Antibodies and reagents
Cdk5 (Abcam, Cambridge, UK; clone 2G2), cytokeratin 5 (Abcam, EP1601Y),
cytokeratin 8 (BioLegend, London, UK; clone 1E8), drebrin (GeneTex,
Isleworth, UK; GTX11068), drebrin (Abcam 176318 & 178408), drebrin
(Progen, Heidelberg, Germany; clone Mx823), EB1 (BD Transduction
Laboratories, Oxford, UK; clone 5), EB3 (Millipore, Consett, UK; AB6033),
p35 (Abcam, ab66064), GAPDH (GeneTex, clone GT239), GFP (Abcam,
Figure 3. BTP2 and drebrin knockdown inhibit PC-3 cell invasion in 3D assays in the presence of CXCL12 chemotactic gradients.
(a, b) Micrographs of cresyl violet-stained PC-3 cells on the lower surface of the insert membrane from 3D invasion assays using control (Con)
or BTP2 (5 μM) treated cultures. (c) Effects of BTP2 on PC-3 cell invasion in a 3D invasion assay. PC-3 cells were incubated in suspension with
vehicle (Con) or with different concentrations of BTP2 for 1 h before re-addition of vehicle or BTP2 and then plating onto Matrigel in the
Transwell insert. After 48 h, cells on the lower surface of the insert membrane were stained with cresyl violet and counted. Error bars are
mean± s.e.m. from four independent experiments each of two replicates per condition. Signiﬁcant differences: **Po0.01; ***Po0.001.
(d) PC-3 cells transfected with GFP, wild-type drebrin-GFP or K270M, K271M drebrin-GFP show similar levels of protein expression.
Immunoblots of transfected PC-3 cells were probed with antibodies against drebrin and GAPDH. The drebrin antibody recognizes
endogenous drebrin (endo-dreb) and the expressed protein (dreb-GFP). (e) Effects of a BTP2-drebrin-binding mutant on BTP2 inhibition of
PC-3 cell invasion in a 3D invasion assay. Cells were transfected with GFP, wild-type drebrin-GFP or K270M, K271M drebrin-GFP and incubated
with BTP2 (10 μM) for 1 h followed by re-addition of BTP2 (10 μM) before seeding onto Matrigel in the Transwell insert. After 48 h, cells on the
lower surface of the insert membrane were stained with cresyl violet and counted. Error bars are mean± s.e.m. from four independent
experiments each of two replicates per condition. Signiﬁcant differences: *Po0.05; ***Po0.001. (f) Immunoblots of PC-3 cells transfected
with either control siRNA (Con siRNA) or drebrin siRNA 1 or drebrin siRNA 2 and probed with antibodies against drebrin and GAPDH, as a
loading control. (g) Quantiﬁcation of relative drebrin protein levels from immunoblots of PC-3 cells transfected with control siRNA (Con siRNA)
or drebrin siRNA 1 or drebrin siRNA 2. Drebrin-speciﬁc siRNAs knockdown drebrin levels by 485% compared to control. Error bars are
mean± s.e.m. from two independent experiments. Signiﬁcant differences: **Po0.01, ***Po0.001. (h) Effects of siRNA knockdown of drebrin
on PC-3 cell invasion in a 3D invasion assay. Cells were transfected with control siRNA (Con siRNA) or drebrin siRNA 1 or drebrin siRNA 2 before
seeding onto Matrigel in the Transwell insert. After 48 h, cells on the lower surface of the insert membrane were stained with cresyl violet and
counted. Error bars are mean± s.e.m. from four independent experiments each of two replicates per condition. Signiﬁcant difference:
***Po0.001. (i) Effects of over-expression of drebrin on PC-3 cell invasion in a 3D invasion assay. Cells were transfected with drebrin-YFP or
YFP alone before seeding onto Matrigel in the Transwell insert. After 48 h, cells on the lower surface of the insert membrane were stained with
cresyl violet and counted. Error bars are mean± s.e.m. from three independent experiments each of two replicates per condition. Signiﬁcant
difference: **Po0.01.
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Figure 4. Drebrin knockdown inhibits PC-3 cell invasion by attenuating polarization and the chemotactic response to a CXCL12 gradient.
(a) Selected frames from phase contrast videos of PC-3 cells in Matrigel in chemotaxis chambers. The source of CXCL2 is to the left. After 48 h,
PC-3 cells have become polarized, extending pseudopods with ﬁlopodia (arrowheads) and have oriented towards the CXCL12 gradient. The
cell has moved across the ﬁeld from right to left, as indicated by a trail of degraded Matrigel (white arrowheads). Elapsed time in hours and
minutes is indicated in the top right-hand corner. (b, c) Polar plots showing the invasive response of PC-3 cells to a gradient of CXCL12 in 3D
Matrigel culture. Cells were treated with: (b) vehicle (DMSO) or 5 μM BTP2, or (c) drebrin siRNA or control siRNA (Con siRNA) and cultured in
Matrigel in chemotaxis chambers with or without a CXCL12 gradient. The source of CXCL12 is to the left. The orientation of degradation trails
with respect to the gradient of CXCL12 was recorded after 48 h in culture. At least 20 cells were counted from each condition in each of three
independent experiments. The radial black line shows the mean for the data and the circumferential line the 95% tolerance limits. A red
circumferential line indicates that the conﬁdence limits are unreliable. (d) Filopodia length of rounded PC-3 cells transfected with control
siRNA (Con siRNA) or drebrin siRNA in 3D Matrigel in a concentration gradient of CXCL12 at 24 h. Filopodia lengths on the gradient-facing, left
side of the cell were compared with those on the opposite, right side of the cell. Numbers are for three independent experiments. The
ﬁlopodia of at least ﬁve cells were counted from each condition in each experiment. Signiﬁcant difference: ***Po0.001. (e) Proportion of
ﬁlopodia containing dynamic microtubules in rounded PC-3 cells transfected with control siRNA (Con siRNA) or drebrin siRNA in 3D Matrigel
in a concentration gradient of CXCL12 at 24 h. Filopodia on the gradient-facing, left side of the cell were compared with those on the
opposite, right side of the cell. Numbers are mean± s.e.m. for two independent experiments. The ﬁlopodia of at least 10 cells were counted
from each condition in each experiment. Signiﬁcant difference: *Po0.05.
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6556), laminin (Sigma-Aldrich, Poole, UK; clone LAM-89), p35/25 (Cell
Signaling, Hitchin, UK; C64B10), p63 (Abcam, ab735 clone BC4A4), pERK1/2
(Thr202/Tyr204) antibody (Cell Signaling; #9101), pS142-drebrin (Millipore,
clone 3C14), tyrosinated α-tubulin (SeroTec, Kidlington, UK; clone YL 1/2),
vimentin (Dako, Glostrup, Denmark; clone V9). Horseradish peroxidase-
conjugated secondary antibodies were from Dako. Alexa-conjugated
secondary antibodies and phalloidin were from Life Technologies,
Warrington, UK. BTP2 (YM-58483) was from Cambridge Bioscience
(Cambridge, UK; CAY13246). Recombinant human CXCL12 was from
PeproTech (London, UK; 300-28A). Matrigel was from Corning (New York,
USA; 354234) and ﬁbronectin from Millipore.
Cell culture
Human prostate cell lines (DU-145, LNCaP, LNCap C4-2B, PC-3 and PNT2-
C2) were maintained in RPMI medium supplemented with 10% fetal
bovine serum (Sigma-Aldrich), 1% Glutamax and penicillin/streptomycin
(50 μg/ml; Life Technologies). All cell lines were grown in a humidiﬁed
incubator at 37 °C and 5% CO2. Cell lines were from ECACC and replaced
every 4 months.
DNA constructs and transfections
The K270M, K271M drebrin-GFP mutant, CFP-EB1M and CFP-EB3M
have been described.2,22 Cells were transfected using X-tremeGENE HP
(Roche, Welwyn Garden City, UK) following manufacturer’s instructions.
Drebrin knockdown was achieved using ON-TARGETplus human drebrin
siRNA (Dharmacon, Lafayette, USA; LU-011841-00-0002) with the following
target sequences: GGAUUAACCGAGAGCAGUU (drebrin siRNA 1),
CCUCAAGCUUGCAGCAUCA (drebrin siRNA 2) or ON-TARGETplus human
drebrin SMARTpool siRNA (Dharmacon; L-011841-00-0005) with the
following target sequences: GGAGGAGGCAGCAGCUAUU, GGAUUAA
CCGAGAGCAGUU, CCUCAAGCUUGCAGCAUCA, GGAGUUUGCCCAAUCGGAA.
EB1 and EB3 knockdown was achieved using ON-TARGETplus human EB1
and EB3 siRNA (Dharmacon; LU-006824-00-0002 and LU-013109-00-0002)
with the following target sequences, EB1: UGACAAAGAUCGAACAGUU
(EB1 siRNA 1), AGAUGAAGGCUUUGUGAUA (EB1 siRNA 2), and EB3:
CAGCAAACUUCGUGACAUC (EB3 siRNA 1), UGAGACUGAUGCCCAAAUU
(EB3 siRNA 2) or ON-TARGETplus human EB1 and EB3 SMARTpool
siRNA (Dharmacon; L-006824-00-0005 and L-013109-00-0005) with
the following target sequences, EB1: GGAAAGCUACGGAACAUUG,
AAACGACCCUGUAUUGCAG, UGACAAAGAUCGAACAGUU, AGAUGAAGG
CUUUGUGAUA, and EB3: CCUCAACUAUACCAAGAUA, CAGCAAACU
UCGUGACAUC, GUAGAGAAAUUAGUGAAAG, UGAGACUGAUGCCCAAAUU.
An ON-TARGETplus non-targeting control pool was also purchased from
Dharmacon (D-001810-10-05). Cells were transfected with control, drebrin,
EB1 and EB3-speciﬁc oligos using HiPerFect Transfection Reagent (Qiagen,
Germantown, MD, USA) following manufacturer's instructions.
Figure 5. Evidence for a role for drebrin/EB3 interactions in PC-3 cell invasion. (a) Immunoblots of a normal human prostate epithelial cell line
(PNT2-C2) and human prostate cancer cell lines probed with antibodies against EB1, EB3 and, as a loading control, GAPDH. (b) Immunoblots of
PC-3 cells expressing CFP, CFP-EB1M, CFP-EB3M, CFP-EB1 or CFP-EB3 probed with an antibody to GFP that cross-reacts with CFP. Expression
levels of related constructs are similar. (c) Effects of transfection of PC-3 cells with CFP, CFP-EB1 CFP-EB3, CFP-EB1M or CFP-EB3M on cell
invasion in a 3D invasion assay in the presence of CXCL12 chemotactic gradients. After 48 h, cells on the lower surface of the insert membrane
were labelled with an antibody to GFP and counted using confocal ﬂuorescence microscopy. Error bars are mean± s.e.m. from four
independent experiments each of two replicates per condition. Signiﬁcant difference: ***Po0.001. NS, not signiﬁcant. (d) Immunoﬂuor-
escence micrographs of PC-3 cells labelled with a GFP antibody that cross-reacts with CFP, and with phalloidin to label F-actin. Cells were
transfected with CFP-EB1M or CFP-EB3M, embedded in Matrigel and exposed to a CXCL12 gradient. PC-3 cells expressing CFP-EB3M are
rounded and produce short ﬁlopodia (arrowheads) but no pseudopods. In contrast, PC-3 cells expressing CFP-EB1M become polarized and
extend pseudopods bearing long, tapered ﬁlopodia (arrows) and short, uniform ﬁlopodia (arrowheads).
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3D in vitro Transwell invasion assay
Matrigel (5 mg/ml), in serum-free RPMI, was pipetted into a Transwell insert
(Corning 3422, 8 μm pore diameter) and allowed to set at 37 °C for 1 h.
Suspensions of siRNA-transfected, CFP-transfected or DMSO-, or BTP2-
treated cells were prepared at 2.5 × 104 cells in 200 μl of serum-free RPMI
were pipetted on top of the Matrigel layer in the Transwell insert and
500 μl of serum-free RPMI containing 100 ng/ml CXCL12 was added to the
lower chamber. DMSO or BTP2 were re-added to the treated cell
suspensions before plating in the insert. After 48 h, cells that had reached
the lower surface of the insert ﬁlters were ﬁxed with 3% formaldehyde and
Figure 6. EB1 and EB3 contribute to PC-3 cell invasion. (a) Immunoﬂuorescence images of a human prostate cancer PC-3 cell grown on a glass
coverslip and labelled with antibodies against EB1, EB3 and tyrosinated α-tubulin (tyr-tubulin), to identify dynamic microtubules. EB1 localizes
to the tip of dynamic microtubules (arrows) and has a shorter and more distal localization than EB3 (arrowheads). (b) Fluorescence intensity
line plots of EB1 (green), EB3 (red) and tyr-tubulin (blue) in PC-3 cells. (c) Quantitative analysis of the length distribution of EB1 and EB3 on
dynamic microtubules measured from ﬂuorescent intensity line plots in PC-3 cells transfected with either control siRNA (Con siRNA) or EB1
siRNA 1 and 2 or EB3 siRNA 1 and 2 and probed with antibodies against EB1 and EB3. Error bars are mean± s.e.m. from three independent
experiments each of at least thirty measurements. Signiﬁcant difference: ***Po0.001. (d) Immunoblots of PC-3 cells transfected with control
siRNA (Con siRNA) or EB1 siRNA 1 or 2 or EB3 siRNA 1 or 2 and probed with antibodies against EB1, EB3 and GAPDH. EB1 siRNA speciﬁcally
knocks down EB1 levels by 495% compared to control and EB3 siRNA speciﬁcally knocks down EB3 levels by 455% compared to control.
(e) Immunoﬂuorescence images of human prostate cancer PC-3 cells grown on glass coverslips and labelled with antibodies against EB1 and
EB3. Cells were transfected with control siRNA or with EB1 siRNA 1 and 2 or EB3 siRNA 1 and 2. In control cells (Con siRNA), EB1 localizes to the
tip of dynamic microtubules and has a shorter and more distal localization than EB3. In cells lacking EB1 (EB1 siRNA), the distribution of EB3
along microtubules appears normal whereas in cells lacking EB3 (EB3 siRNA), the distribution of EB1 along the microtubule increases.
(f) Effects of EB1 and EB3 knockdown with siRNA on PC-3 cell invasion in a 3D invasion assay in the presence of CXCL12 chemotactic gradients.
Cells were transfected with control siRNA (Con siRNA) or EB1 siRNA 1 or 2 or EB3 siRNA 1 or 2 before seeding onto Matrigel in the Transwell
insert. After 48 h, cells on the lower surface of the insert membrane were stained with cresyl violet and counted. EB3 knockdown has a greater
effect on PC-3 invasion than EB1. Error bars are mean± s.e.m. from four independent experiments each of two replicates per condition.
Signiﬁcant differences: **Po0.01, ***Po0.001.
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0.2% glutaraldehyde in PBS pH 7.2 and then stained with 0.1% w/v cresyl
violet. Stained ﬁlters were viewed under an Olympus BH2 microscope and
images captured with a DP70 digital camera. In the case of invasion assays
with CFP-transfected cells, the cells were ﬁxed as described previously
but the ﬁlters were immunolabelled with GFP antibody followed by
Alexa-conjugated secondary antibody and imaged using an Olympus
FluoView confocal microscope. Cells were counted manually using
ImageJ software (NIH, Bethesda, MD, USA).
MTT viability and Matrigel adhesion assays
MTT viability assay was performed as described.43 For adhesion assays,
cells were pre-incubated with DMSO or BTP2 in suspension at 37 oC for 1 h.
Glass coverslips were coated with ice-cold Matrigel (5 mg/ml) in serum-free
RPMI and incubated at 37 oC for 1 h to allow the gel to set. DMSO or BTP2
were re-added to the cell suspensions before cells were plated at a density
of 5 × 104 cells per well of a 24-well plate. Cells were allowed to adhere for
1.5 h at 37 oC. Cells were then ﬁxed with 3% formaldehyde and 0.2%
glutaraldehyde in PBS pH 7.2. Cells, labelled with Alexa-conjugated
phalloidin, were imaged using an Olympus FluoView confocal microscope.
Cell numbers were counted manually using ImageJ.
Live cell imaging
Cells were embedded in Matrigel in μ-slide chemotaxis3D chambers (Ibidi,
Glasgow, UK; IB-80326) following the manufacturer’s instructions. For drug
treatments, cell suspensions were incubated at 37 °C for 1 h in the
presence of the drug. Subsequently, cell suspensions were mixed with ice-
cold Matrigel (5 mg/ml). DMSO and BTP2 were re-added at this stage. The
cell/gel mixture (6 μl) was immediately pipetted into the central
observation area of the chemotaxis chamber. The chamber was then
covered with the lid and incubated in a humidiﬁed 10 cm Petri dish in an
incubator at 37 °C for 30 min until the Matrigel had set. Both reservoirs
either side of the observation area were then ﬁlled with 65 μl serum-free
RPMI. To establish a chemotactic gradient across the chamber, 15 μl of
200 ng/ml CXCL12 in serum-free RPMI was pipetted into the bottom ﬁlling
port of the left reservoir before removing 15 μl from the top port. This step
was repeated once more so that the resulting concentration of
chemoattractant in the left reservoir was 0.5 times the injected
concentration, that is, 100 ng/ml. Time-lapse phase contrast imaging was
performed with an Olympus IX70 inverted microscope equipped with an
environmental chamber (Solent) using phase contrast objectives. Cultures
were maintained at 37 °C and gassed with CO2. Images were captured with
a Hamamatsu 9100 EM-CCD camera and processed in ImageJ.
For cell motility assays, PC-3 cells were cultured in opti-MEM Medium
supplemented with 10% fetal bovine serum at 37 °C in 6-well plates coated
with ﬁbronectin (10 μg/ml). Phase contrast images (100) at 10 min intervals
were captured in the presence of DMSO (vehicle control) or different
concentrations of BTP2. Speed of motility was quantiﬁed using the Cell
Tracker plug-in of ImageJ.
3D chemotaxis chamber immunoﬂuorescence
Cells in chemotaxis chambers were ﬁxed for 20 min with 3% formaldehyde
and 0.2% glutaraldehyde in PBS pH 7.2 at 37 °C or with 3% formaldehyde,
0.2% glutaraldehyde and 0.2% Triton-X-100 in PHEM buffer pH 6.9. Cells
were washed with PBS and then incubated in blocking buffer (BB; 5% (v/v)
normal horse serum, 5% (v/v) normal goat serum, 50 mM L-lysine and 0.2%
(v/v) Triton X-100 in PBS pH 7.2) for 2 h at room temperature (RT) followed
by incubation with primary antibodies in BB for 1 h at RT and then
overnight at 4 °C. Cells were washed with PBS before incubation with
Alexa-conjugated secondary antibodies and phalloidin in BB for 4 h at RT.
After washing with PBS, cells were imaged using an Olympus FluoView
confocal microscope.
Immunoblotting
Proteins were extracted from frozen human prostate tissue using RIPA
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20 mM
NaF, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 0.5% (v/v) Na deoxycholate)
supplemented with protease and phosphatase inhibitors (Sigma-Aldrich).
Cultured cells were washed in PBS and lysed in either hot 5x Lamelli
sample buffer or RIPA buffer. For RIPA lysed samples, protein concentration
was determined using BioRad (Hemel Hempstead, UK) Protein Assay
reagent and between 10 μg to 50 μg loaded into each well of SDS-PAGE
gels. Gels were transferred onto polyvinylidene diﬂuoride membranes
(Thermo, Paisley, Scotland, UK) and blocked overnight in 5% milk/Tris-
buffered saline Triton X-100. Primary antibodies were incubated for 1 h at
37 °C or overnight at 4 °C and secondary antibodies for 1 h at RT. Blots
were developed with enhanced chemiluminescent kits (Millipore) and
either, imaged and analysed using a Li-Cor Odyssey Fc, or exposed to clear
blue X-ray ﬁlms (Photon Imaging Systems, Swindon, UK). Films were
developed in a Fuji processor, scanned using an Epsom V500 ﬂat-bed
scanner and analysed in ImageJ.
CXCL12 stimulation of PC-3 cells
PC-3 cells were plated at 1 × 105 cells per well of a 6-well plate and
incubated overnight at 37 °C in complete medium. Prior to CXCL12
stimulation, the complete medium was replaced with serum-free medium
and cells incubated for a further 3 h at 37 °C. One well was left in complete
medium. Cells were then treated with CXCL12 (100 ng/ml) in serum-free
medium for 2, 5, 10 or 20 min. Cells were then lysed on ice with RIPA
buffer. Lysates were run on Western blots and probed with pS142-drebrin
antibody and pERK1/2 antibody, as a control for induction of protein
phosphorylation.
Immunoﬂuorescence of cultured cells
Cells were plated onto glass coverslips (13 mm) coated with 10 μg/ml
ﬁbronectin (Sigma-Aldrich) and, following attachment, were ﬁxed for
10 min either with 3% formaldehyde and 0.2% glutaraldehyde in PBS pH
7.2 or 3% formaldehyde, 0.2% glutaraldehyde and 0.2% Triton X-100 in
PHEM buffer pH 6.9 at 37 °C. For EB1 and EB3 immunolabelling, cells were
serum starved for 3 h before re-addition of serum for 1 h, to induce cell
spreading, followed by ﬁxation with methanol for 15 min at –20 oC and 4%
formaldehyde in PBS for 10 min. Cultures were then incubated in BB at RT
for 1 h followed by incubation in primary antibody in BB at RT for 1 h.
Cultures were then washed with PBS and incubated in Alexa-conjugated
secondary antibodies and phalloidin, to visualize F-actin, in BB for 1 h at RT.
Finally, cultures were washed with PBS and mounted in FluorSave anti-fade
reagent (Millipore). Labelled cultures were imaged using an Olympus
FluoView confocal microscope. Fluorescence intensity line plots of
microtubules and EB proteins were acquired using the Line tool and
analysed using Plot Proﬁle in ImageJ.
Immunoﬂuorescence of human prostate tissue
Tissue was obtained from consenting patients following local ethical
committee approval. Frozen sections of human prostate were ﬁxed with
4% formaldehyde in PBS pH 7.2 at 4 oC for 20 min. Sections were washed
with PBS and then incubated in BB at RT for 1 h followed by incubation in
primary antibody in BB at RT for 2 h. Sections were then washed with PBS
and incubated in Alexa-conjugated secondary antibodies and phalloidin in
BB at RT for 2 h. Labelled sections were viewed using an Olympus FluoView
confocal microscope. Fluorescent images in TIFF format were manipulated
using Adobe Photoshop.
Immunohistochemistry of prostate tissue
Tissue microarray sections were obtained from the Oxford Centre for
Histopathology Research, Oxford University Hospitals NHS Foundation
Trust, Oxford, UK. Microscope slide-mounted tissue sections were
deparafﬁnized, hydrated and exposed to a rabbit polyclonal antibody
against drebrin (GeneTex, 1:500) or a mouse monoclonal antibody against
pS142-drebrin4 (1:100) overnight following antigen retrieval using citrate
buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.5) for 20 min at 90 °C
in a microwave oven. Pre-diluted ImmPACT secondary antibody (Vector
Labs, Peterborough, UK) was applied to the slides for 30 min and ImmPACT
DAB (Vector Labs) was added to observe positive stain. Negative controls
for immunohistochemistry included replacing primary antibody with horse
serum. Samples were evaluated microscopically and digital photographs
were taken with a 20 objective. Following immunohistochemistry, the
maximum protein expression intensity in prostate epithelial cells (benign
or malignant; 0–3, with 3 = strong expression, 2 =moderate expression,
1 =weak expression and 0=no expression), and the percentage of
prostate epithelial cells with that maximum expression (0–100%), was
assigned for each core by a single expert uropathologist blinded to the
study hypothesis. The maximum protein intensity (0–3) and percentage
(0–100) scores were multiplied to give a ﬁnal expression score for each
core sample (range 0–300). The tissue microarray was built and this part of
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the study conducted under the Oxford Radcliffe Biobank ethics committee
approval (reference number 09/H0606/5+5).
Statistical analysis
In vitro data were analysed using GraphPad Prism 5 (GraphPad Software, La
Jolla, CA, USA) or, for polar plots, Oriana 4 (Kovach Computing Services,
Pentraeth, Wales, UK), and expressed as mean± s.e.m. The unpaired two-
tailed Student’s t-test or ANOVA test was used for statistical analysis.
Differences between values in all statistical tests were considered
signiﬁcant if Po0.05. Associations between mRNA expression or copy
number groups and sample type (primary or metastasis) from the MSKCC
Prostate Cancer Genomics Data Portal were investigated using the χ2-test.
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